Retained Earnings (Accumulated Deficit) of Neumora Therapeutics, Inc. from 31 Dec 2022 to 30 Sep 2025

Taxonomy & unit: us-gaap: USD
Description: The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary: Neumora Therapeutics, Inc. quarterly Retained Earnings (Accumulated Deficit) in USD history and change rate from 31 Dec 2022 to 30 Sep 2025.
Neumora Therapeutics, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending 30 Sep 2025 was $1,124,699,000, a 27% decline year-over-year.
Source SEC data: View on sec.gov

Retained Earnings (Accumulated Deficit), Quarterly (USD)

Retained Earnings (Accumulated Deficit), YoY Quarterly Change (%)

Neumora Therapeutics, Inc. Quarterly Retained Earnings (Accumulated Deficit) (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2025	$1,124,699,000	-$236,297,000	-27%	30 Sep 2025	10-Q	06 Nov 2025	2025	Q3
Q2 2025	$1,067,944,000	-$252,089,000	-31%	30 Jun 2025	10-Q	06 Aug 2025	2025	Q2
Q1 2025	$1,015,213,000	-$258,058,000	-34%	31 Mar 2025	10-Q	12 May 2025	2025	Q1
Q4 2024	$947,221,000	-$243,787,000	-35%	31 Dec 2024	10-Q	06 Nov 2025	2025	Q3
Q3 2024	$888,402,000	-$293,698,000	-49%	30 Sep 2024	10-Q	12 Nov 2024	2024	Q3
Q2 2024	$815,855,000			30 Jun 2024	10-Q	06 Aug 2024	2024	Q2
Q1 2024	$757,155,000			31 Mar 2024	10-Q	07 May 2024	2024	Q1
Q4 2023	$703,434,000	-$235,925,000	-50%	31 Dec 2023	10-K	03 Mar 2025	2024	FY
Q3 2023	$594,704,000			30 Sep 2023	10-Q	01 Nov 2023	2023	Q3
Q4 2022	$467,509,000			31 Dec 2022	10-K	07 Mar 2024	2023	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.